How three nearby genes affect tumor risk in Neurofibromatosis type 1
Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1
This project looks at how changes in three tumor-suppressor genes (p16/ARF/p15) may help predict and prevent dangerous nerve tumors in people with neurofibromatosis type 1.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11290319 on NIH RePORTER |
What this research studies
From my perspective, the researchers will study why some benign plexiform neurofibromas turn into malignant peripheral nerve sheath tumors by focusing on three linked tumor-suppressor genes called p16Ink4a, ARF, and p15Ink4b. They will compare genetic and protein changes in patient-derived tumor samples and use cell and animal models to see how losing one or more of these genes affects tumor behavior. The team will also test drugs that act on the pathways controlled by these genes to see if they can block or slow malignant transformation. The aim is to better classify precancerous lesions and point toward tests or treatments to lower the risk of deadly MPNSTs.
Who could benefit from this research
Good fit: People with neurofibromatosis type 1—especially those who have plexiform neurofibromas, atypical neurofibromas, or who can donate tumor tissue—are the best fit for this research.
Not a fit: People without NF1 or those with unrelated medical conditions are unlikely to gain direct benefit from this laboratory-focused work in the near term.
Why it matters
Potential benefit: If successful, this work could help identify which nerve tumors in NF1 patients are most likely to become cancerous and guide new targeted therapies to prevent or treat MPNSTs.
How similar studies have performed: Previous studies have linked loss of CDKN2A/CDKN2B genes to MPNSTs and drugs targeting these pathways have shown promise in other cancers, but applying these findings specifically to NF1-related tumor progression is still relatively new.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Dodd, Rebecca D — University of Iowa
- Study coordinator: Dodd, Rebecca D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.